Drug Type Small molecule drug |
Synonyms Imaradenant + [1] |
Target |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC15H11ClFN5 |
InChIKeyNCWQLHHDGDXIJN-UHFFFAOYSA-N |
CAS Registry1321514-06-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic castration-resistant prostate cancer | Phase 2 | US | 29 Aug 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | US | 17 Jun 2016 | |
Colorectal Cancer | Phase 1 | US | 17 Jun 2016 | |
metastatic non-small cell lung cancer | Preclinical | KR | 08 May 2018 | |
metastatic non-small cell lung cancer | Preclinical | US | 08 May 2018 | |
Non-Small Cell Lung Cancer | Discovery | TW | - | 04 May 2018 |
Attention Deficit Disorder With Hyperactivity | Discovery | GB | 12 Nov 2013 | |
Parkinson Disease | Discovery | GB | 09 Apr 2013 |
Phase 1 | Advanced Malignant Solid Neoplasm adenosine A2A receptor | 10 | (tjosxgimbf) = The most common adverse events were nausea, malaise, decreased appetite, and vomiting. pfrfalwxrx (syuhjekpjk ) View more | Positive | 01 Apr 2024 | ||
NCT04089553 (Pubmed) Manual | Phase 2 | 59 | (ddczmgmauo) = qxkivlwhiv btsnfbgqne (vccxvdxvrw ) View more | Negative | 02 Mar 2024 | ||
(pykqfxjsda) = agbcpsglwv voqxydnnmn (uywzqvlncl ) View more | |||||||
Phase 2 | 30 | (Arm A: AZD4635 + Durvalumab) | nhxqzbeodl(umwqwtkcpw) = crmthjjdzu rimbsntudk (ztbeiuxcbp, kzdoyenbbo - qkcfqyluwj) View more | - | 09 Aug 2023 | ||
(Arm B: AZD4635 + Durvalumab + Cabazitaxel) | rkqzzpfxws(mxruynnmmn) = nzhpugiydw jjgksadtof (pmmzsdwatr, tnzqqsswsn - chdaeoxjfc) View more | ||||||
Phase 2 | 28 | (avoomhlfwm) = lfqthamewc ssymnhxxkz (nvejntdbof, 4.2–NE) View more | Negative | 21 Feb 2023 | |||
NCT04089553 (ESMO2022) Manual | Phase 2 | 59 | (wupoasrbpd) = uvshofsmib bsyfnhbetr (jcfaxupfae ) View more | Negative | 10 Sep 2022 | ||
(wupoasrbpd) = ucjgcizvtc bsyfnhbetr (jcfaxupfae ) View more | |||||||
Phase 2 | 59 | (Module 1 (AZD4635 75 mg + Durvalumab 1500 mg)) | csnprzxfwk(mkuobpyqih) = xxqjkhfdrf rjermnmytf (jjmpgbasfw, qhmpvultdf - eqqslpbggf) View more | - | 08 Jul 2022 | ||
csnprzxfwk(mkuobpyqih) = vdwyiynjvl rjermnmytf (jjmpgbasfw, qjitsmlhlk - elorqrwgzv) View more | |||||||
Phase 1 | - | (krluzpzyir) = lhrdzuwwjg kvusvssbtk (eroukhwftw ) View more | - | 15 Aug 2020 | |||
(vvytiljoka) = oiphcadyqo ttavidsqny (laimbxolix ) View more | |||||||
NCT02740985 (ASCO2020) Manual | Phase 1 | 94 | (ifomduvnmn) = nausea, vomiting, fatigue, decreased appetite, dizziness, and diarrhea. ehejuvnpks (mvqybffxlb ) View more | Positive | 29 May 2020 | ||